Sab biotherapeutics appoints katie ellias to the board of directors

Sioux falls, s.d., nov. 20, 2023 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced that katie ellias has been appointed to the company's board of directors.

SABS Ratings Summary

SABS Quant Ranking